Acetic Acid

Acetic Acid

SCHEMBL2481280

CC(=O)O.CCC1(COS(C)(=O)=O)CC1

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MMP9 P14780 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL799912 0.90 KDM4E (0.37) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL323068 0.80 USP2 (0.42) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL625985 0.79 CYP1A2 (0.37) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL18256652 0.78 KDM4E (0.31) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL16028550 0.76 KDM4E (0.36) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL2614521 0.75 KDM4E (0.34) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL1662342 0.74 GAA (0.36) ALDH1A1
SCHEMBL1039373 0.73 TSHR (0.34) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL1484479 0.73 TP53 (0.33) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL9788176 0.73 KDM4E (0.30) KDM4EUSP2ALDH1A1LMNAMMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2181986-B1 Process for the preparation of a precursor of montelukast SYNTHON BV (NL) 2011-10-19 EP disclosed
EP-2181986-A1 Process for the preparation of a precursor of montelukast Synthon B.V. (NL) 2010-05-05 EP disclosed
US-7501517-B2 Process for making montelukast and intermediates therefor SYNTHON IP, INC. (US) 2009-03-10 US disclosed
EP-1740546-A2 PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR Synthon B.V. (NL) 2007-01-10 EP disclosed
WO-2005105749-A2 PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR SYNTHON B.V. (NL) 2005-11-10 WO disclosed
US-20050245569-A1 Process for making montelukast and intermediates therefor SYNTHON IP INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245569-A1 Process for making montelukast and intermediates therefor LTA4H, CYP4A11, LTC4S KDM4E 3340/4885USP2 2783/4885ALDH1A1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.